Who is sponsoring NCT04265430?

NCT04265430 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT04265430?

Interventions in NCT04265430: Contrast Agent, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration.

What condition does NCT04265430 study?

NCT04265430 studies Malignant Oral Cavity Neoplasm, Malignant Skull Base Neoplasm, Osteoradionecrosis.

Is NCT04265430 still recruiting?

NCT04265430 is currently recruiting now. Last updated 14 November 2025.

Last reviewed 2025-11-14 · How we verify

NCT04265430

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors

Recruiting now Phase 4 Last updated 14 November 2025

What this trial tests

Phase 4 trial testing Contrast Agent in Malignant Oral Cavity Neoplasm in 425 participants. Currently enrolling.

Timeline

17 September 2018

Primary endpoint
1 September 2031

1 September 2031

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	425
Start date	17 September 2018
Primary completion	1 September 2031
Estimated completion	1 September 2031
Sites	1 location across United States

Drugs / interventions tested

Contrast Agent — full drug profile →
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration

Conditions studied

Malignant Oral Cavity Neoplasm — all drugs for Malignant Oral Cavity Neoplasm →
Malignant Skull Base Neoplasm — all drugs for Malignant Skull Base Neoplasm →
Osteoradionecrosis — all drugs for Osteoradionecrosis →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Malignant Oral Cavity Neoplasm or Malignant Skull Base Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase IV trial studies how well serial magnetic resonance imaging (MRI) after radiation therapy works in predicting radiation-induced changes in the normal tissue of patients with oral cavity or skull base tumors. Performing MRIs after radiation therapy for patients with oral cavity or skull base tumors may help to predict osteoradionecrosis (a change in non-cancerous tissue).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Hypomagnesemia and incidence of osteoradionecrosis in patients with head and neck cancers.
Liu W, Qdaisat A, Zhou S, Fuller CD, et al · · 2021 · cited 4× · PMID 33094893 · DOI 10.1002/hed.26510
Black bone MRI morphometry for mandibular cortical bone measurement in head and neck cancer patients: prospective method comparison with CT.
van Dijk LV, Ventura J, Wahid KA, Zhu LL, et al · · 2026 · cited 3× · PMID 41702795 · DOI 10.1016/j.oooo.2025.12.013
MRI Intensity Standardization Evaluation Design for Head and Neck Quantitative Imaging Applications
Wahid KA, He R, McDonald BA, Anderson BM, et al · · 2021 · cited 1× · DOI 10.1101/2021.02.24.21252322

Verify or expand the search:

Other trials of Contrast Agent

Trials testing the same drug.

NCT06330805 — Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer · Phase 2 · recruiting
NCT05046301 — Contrast-Enhanced Mammography for the Evaluation of Mammographic Microcalcifications · active not recruiting
NCT03176979 — Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer · NA · completed

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04265430 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 14 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04265430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing